SHSE:600196'
s Net Margin % Range Over the Past 10 Years
Min: 5.76 Med: 11.25 Max: 19.18
Current: 8.22
SHSE:600196's Net Margin % is ranked better than 58.58% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs SHSE:600196: 8.22
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Shanghai Fosun Pharmaceutical (Group) Co Net Margin % Related Terms
Shanghai Fosun Pharmaceutical (Group) Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co Net Margin % Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co Net Margin % vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) has a Net Margin % of 8.64% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. This is 23% below median its historical median of 11.25. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's Net Margin % has ranged from 5.76 to 19.18. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #396 out of 956 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is Shanghai Fosun Pharmaceutical (Group) Co's Net Margin % too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Net Margin % of 8.64% is 23% below median its 10-year median of 11.25. Over the past 10 years, this metric has ranged from a low of 5.76 to a high of 19.18. The Drug Manufacturers industry median Net Margin % is 5.56. Shanghai Fosun Pharmaceutical (Group) Co's value of 8.64% is 55.4% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #396 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #396 out of 956 companies for Net Margin %. This puts Shanghai Fosun Pharmaceutical (Group) Co in the upper half of its industry. The industry median Net Margin % is 5.56. Shanghai Fosun Pharmaceutical (Group) Co's value of 8.64% is 55.4% above this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own Net Margin % has ranged from 5.76 to 19.18 over the past decade. While the company's 10-year median is 11.25 vs. the industry median of 5.56, Shanghai Fosun Pharmaceutical (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current Net Margin % of 8.64% is 55.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current Net Margin % is 8.64%, which is 23% below median its own 10-year median of 11.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥27.07, compared to a current price of ¥21.21 — trading 21.6% below its estimated fair value. The current Net Margin % is 8.64%, which is 23% below median its 10-year median of 11.25 and 55.4% above the Drug Manufacturers industry median of 5.56. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196), the current Net Margin % is 8.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SHSE:600196) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of ¥21.21 is trading 21.6% below its estimated GF Value™ of ¥27.07.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600196:
Net Margin %: 8.64% (23% below median its 10-year median of 11.25)
GF Value™: ¥27.07 vs. price of ¥21.21 (21.6% below fair value)
Industry Position: 55.4% above the Drug Manufacturers median (#396 of 956)
No single metric tells the full story. See the SHSE:600196 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
76GF Score
Get the complete analysis for SHSE:600196
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600196 has been successfully added to your 
